Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients

Status Completed

Clinical Trial Summary

This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of macrogol 3350-based oral osmotic laxative may stop cancer from growing in patients who are at risk of colorectal cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the effect of polyethylene glycol (PEG) 3350 (administered at 8 g or 17 g/day for six months) versus placebo on epidermal growth factor receptor (EGFR) expression.

SECONDARY OBJECTIVES:

I. To determine the effect of PEG 3350 on aberrant crypt foci (ACF) number and to compare the reduction in ACF number between the low dose (8 g PEG 3350/day) and higher dose (17 g PEG 3350/day) groups.

II. To determine the effect of PEG 3350 on mucosal epithelial proliferation (marker of proliferation Ki-67 [Ki-67]).

III. To determine the effect of PEG 3350 on mucosal apoptosis (cleaved caspase-3).

IV. To determine the effect of PEG 3350 on snail family zinc finger 1 (SNAIL) protein expression.

V. To determine the effect of PEG 3350 on messenger ribonucleic acid (mRNA) expression of SNAIL and EGFR.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM A: Patients receive high-dose macrogol 3350-based oral osmotic laxative orally (PO) once daily (QD).

ARM B: Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD.

ARM C: Patients receive placebo (i.e., maltodextrose powder) PO QD.

In all arms, treatment begins within 6-10 days after colonoscopy and continues for up to 6 months in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed at 30 days. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00828984
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	October 2009
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04444232` - Cancer Communication Within Hispanic Social Networks	N/A
Recruiting	`NCT06233253` - Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy	N/A
Recruiting	`NCT05799820` - QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC	Phase 2
Recruiting	`NCT04666727` - Role of Diet on the Microbiome of the Digestive System
Recruiting	`NCT04767984` - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis	Phase 2
Recruiting	`NCT02376452` - Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients	Phase 2
Completed	`NCT02254486` - Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults	Phase 3
Completed	`NCT01486251` - Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer	N/A
Terminated	`NCT01233544` - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases	Phase 3
Recruiting	`NCT02073500` - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed	`NCT00704600` - Nelfinavir, a Phase I/Phase II Rectal Cancer Study	Phase 1/Phase 2
Completed	`NCT00485316` - Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma	Phase 3
Recruiting	`NCT04430738` - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	Phase 1/Phase 2
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT05022511` - Three Birds With One Stone	N/A
Completed	`NCT04607291` - Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening	Phase 1
Not yet recruiting	`NCT03969784` - Microparticles in Peritoneal Carcinomatosis of Colorectal Origin	N/A
Not yet recruiting	`NCT05630794` - Testing ONC201 to Prevent Colorectal Cancer	Phase 1
Terminated	`NCT05291988` - A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial	N/A
Suspended	`NCT04108481` - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms